Barcelona patent court finds oxycodone and naloxone patent invalid due to added matter

On 19 December 2018 Barcelona Commercial Court Number 4 dismissed a patent infringement action brought by Mundipharma against two generics of its oxycodone and naloxone medicinal product for the treatment of pain (Targin) and upheld the defendants’ counterclaim that the asserted patent was invalid. Facts Mundipharma holds European Patent EP2425825 (EP’825), entitled ‘Pharmaceutical preparation containing…

Jesús Arribas | Grau & Angulo Abogados

Jesús Arribas participó como ponente en las XIII Jornadas del Tribunal de Marcas de la Unión Europea

Nuestro socio Jesús Arribas participó, como ponente, en las XIII Jornadas del Tribunal de Marcas de la Unión Europea que se celebraron en Alicante el 15 y 16 de noviembre. Su intervención se centró en las medidas cautelares urgentes y escritos preventivos en ferias y eventos.

Spain Chapter / Trademark Review Yearbook 2019/2020

  – Patent, Trademark, Copyright & Design litigation – Advice on licence agreements •Anti-counterfeiting actions – Domain name disputes – Unfair competition Authors Sonia Santos and Jesús Arribas   Download   This article first appeared in World Trademark Review Yearbook 2019/2020, a supplement to World Trademark Review, published by Globe Business Media Group – IP Division. To view the…

Nuria Ribera | Grau & Angulo Abogados

Barcelona courts lift preliminary injunctions previously granted ex parte in oxycodone/naloxone case

Through two decisions issued on July 18 and 19 2017, Barcelona Commercial Court Number 4 and Barcelona Commercial Court Number 1, respectively, lifted the preliminary injunctions that they had previously granted ex parte at the request of Mundipharma in relation to the imminent market launch of two oxycodone/naloxone generic medicinal products. Facts Mundipharma is the holder of…